AstraZeneca to buy 55% of biotech firm Acerta for $4b, to get cancer drug

AstraZeneca to buy 55% of biotech firm Acerta for $4b, to get cancer drug

A sign is seen at an AstraZeneca site in Macclesfield, central England in this May 19, 2014 file photo. REUTERS/Phil Noble

AstraZeneca is to buy 55 percent of privately held biotech firm Acerta Pharma for $4 billion to give it access to a new kind of blood cancer drug, boosting its long-term growth at the cost of a near-term hit to earnings.

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter